345 related articles for article (PubMed ID: 17955243)
1. Minimal change nephropathy and focal segmental glomerulosclerosis.
Mathieson PW
Semin Immunopathol; 2007 Nov; 29(4):415-26. PubMed ID: 17955243
[TBL] [Abstract][Full Text] [Related]
2. Podocyte-Specific Induction of Krüppel-Like Factor 15 Restores Differentiation Markers and Attenuates Kidney Injury in Proteinuric Kidney Disease.
Guo Y; Pace J; Li Z; Ma'ayan A; Wang Z; Revelo MP; Chen E; Gu X; Attalah A; Yang Y; Estrada C; Yang VW; He JC; Mallipattu SK
J Am Soc Nephrol; 2018 Oct; 29(10):2529-2545. PubMed ID: 30143559
[TBL] [Abstract][Full Text] [Related]
3. Connective tissue growth factor modulates podocyte actin cytoskeleton and extracellular matrix synthesis and is induced in podocytes upon injury.
Fuchshofer R; Ullmann S; Zeilbeck LF; Baumann M; Junglas B; Tamm ER
Histochem Cell Biol; 2011 Sep; 136(3):301-19. PubMed ID: 21814837
[TBL] [Abstract][Full Text] [Related]
4. Regulation of TRPC6 ion channels in podocytes - Implications for focal segmental glomerulosclerosis and acquired forms of proteinuric diseases.
Szabó T; Ambrus L; Zákány N; Balla G; Bíró T
Acta Physiol Hung; 2015 Sep; 102(3):241-51. PubMed ID: 26551740
[TBL] [Abstract][Full Text] [Related]
5. The role of B7-1 in proteinuria of glomerular origin.
Novelli R; Benigni A; Remuzzi G
Nat Rev Nephrol; 2018 Sep; 14(9):589-596. PubMed ID: 29959373
[TBL] [Abstract][Full Text] [Related]
6. Calcineurin inhibitors ameliorate PAN-induced podocyte injury through the NFAT-Angptl4 pathway.
Shen X; Zhang Y; Lin C; Weng C; Wang Y; Feng S; Wang C; Shao X; Lin W; Li B; Wang H; Chen J; Jiang H
J Pathol; 2020 Nov; 252(3):227-238. PubMed ID: 32686149
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of fibroblast-specific protein-1 expression on podocytes in patients with focal segmental glomerulosclerosis.
Samejima K; Nakatani K; Suzuki D; Asai O; Sakan H; Yoshimoto S; Yamaguchi Y; Matsui M; Akai Y; Toyoda M; Iwano M; Saito Y
Nephron Clin Pract; 2012; 120(1):c1-7. PubMed ID: 22126861
[TBL] [Abstract][Full Text] [Related]
8. Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies.
Eriguchi M; Yotsueda R; Torisu K; Kawai Y; Hasegawa S; Tanaka S; Noguchi H; Masutani K; Kitazono T; Tsuruya K
Am J Physiol Renal Physiol; 2016 Feb; 310(4):F322-33. PubMed ID: 26632605
[TBL] [Abstract][Full Text] [Related]
9. Ultrastructural features and expression of cytoskeleton proteins of podocyte from patients with minimal change disease and focal segmental glomerulosclerosis.
Shi SF; Wang SX; Zhang YK; Zhao MH; Zou WZ
Ren Fail; 2008; 30(5):477-83. PubMed ID: 18569926
[TBL] [Abstract][Full Text] [Related]
10. In situ evaluation of podocytes in patients with focal segmental glomerulosclerosis and minimal change disease.
da Silva CA; Monteiro MLGDR; Araújo LS; Urzedo MG; Rocha LB; Dos Reis MA; Machado JR
PLoS One; 2020; 15(11):e0241745. PubMed ID: 33147279
[TBL] [Abstract][Full Text] [Related]
11. Reduced podocin expression in minimal change disease and focal segmental glomerulosclerosis is related to the level of proteinuria.
Agrawal V; Prasad N; Jain M; Pandey R
Clin Exp Nephrol; 2013 Dec; 17(6):811-8. PubMed ID: 23377573
[TBL] [Abstract][Full Text] [Related]
12. Podocyte expression of nonmuscle myosin heavy chain-IIA decreases in idiopathic nephrotic syndrome, especially in focal segmental glomerulosclerosis.
Miura K; Kurihara H; Horita S; Chikamoto H; Hattori M; Harita Y; Tsurumi H; Kajiho Y; Sawada Y; Sasaki S; Igarashi T; Kunishima S; Sekine T
Nephrol Dial Transplant; 2013 Dec; 28(12):2993-3003. PubMed ID: 24042022
[TBL] [Abstract][Full Text] [Related]
13. Clinical and histological findings of autosomal dominant renal-limited disease with LMX1B mutation.
Konomoto T; Imamura H; Orita M; Tanaka E; Moritake H; Sato Y; Fujimoto S; Harita Y; Hisano S; Yoshiura K; Nunoi H
Nephrology (Carlton); 2016 Sep; 21(9):765-73. PubMed ID: 26560070
[TBL] [Abstract][Full Text] [Related]
14. Direct Effects of Immunomodulatory Agents on Podocytes in Immune-Mediated Glomerular Diseases.
Manabe S; Nitta K; Nagata M
Contrib Nephrol; 2018; 195():131-142. PubMed ID: 29734158
[TBL] [Abstract][Full Text] [Related]
15. Immunoexpression of podocyte-associated proteins in acquired human glomerulopathies with nephrotic syndrome.
Wagrowska-Danilewicz M; Stasikowska O; Danilewicz M
Pol J Pathol; 2006; 57(1):17-21. PubMed ID: 16739878
[TBL] [Abstract][Full Text] [Related]
16. Morphologic Analysis of Urinary Podocytes in Focal Segmental Glomerulosclerosis.
Shirai Y; Miura K; Yokoyama T; Horita S; Nakayama H; Seino H; Ando T; Shiratori A; Yabuuchi T; Kaneko N; Ishiwa S; Ishizuka K; Hara M; Hattori M
Kidney360; 2021 Mar; 2(3):477-486. PubMed ID: 35369007
[TBL] [Abstract][Full Text] [Related]
17. Pathobiology of focal segmental glomerulosclerosis: new developments.
D'Agati VD
Curr Opin Nephrol Hypertens; 2012 May; 21(3):243-50. PubMed ID: 22357339
[TBL] [Abstract][Full Text] [Related]
18. Renal disease. II. The treatment of minimal change nephropathy and focal segmental glomerulosclerosis.
Mason PD
J R Coll Physicians Lond; 1997; 31(2):137-41. PubMed ID: 9131509
[No Abstract] [Full Text] [Related]
19. Vinculin is required to maintain glomerular barrier integrity.
Lausecker F; Tian X; Inoue K; Wang Z; Pedigo CE; Hassan H; Liu C; Zimmer M; Jinno S; Huckle AL; Hamidi H; Ross RS; Zent R; Ballestrem C; Lennon R; Ishibe S
Kidney Int; 2018 Mar; 93(3):643-655. PubMed ID: 29241625
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of podocyte phenotype in idiopathic collapsing glomerulopathy and HIV-associated nephropathy.
Yang Y; Gubler MC; Beaufils H
Nephron; 2002 Jul; 91(3):416-23. PubMed ID: 12119471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
